As a company specializing in biomedical development platform with ingenious immunoassay techniques, Novel Peptide Bioscience Co., Ltd. was registered in Chongqing International Biological City, Banan District in 2020. With the technical support from innovative platforms at the state level and Chongqing Municipality's level such as Chongqing International Institute for Immunology, National Polypeptide Drugs Engineering Laboratory, China National Research Center for Immunobiological Products, National Pilot Production Center of Biological Industry Base and the Company's ingenious antigen engineering theory and technology system, the Company is capable of developing corresponding therapeutic drugs in multiple fields including chronic infectious diseases, tumors, autoimmune diseases and cognitive diseases.

In October 2020, the Company acquired Mendel's all the patents, rights and interests through a therapeutic (synthetic peptide) hepatitis B vaccine technology project transfer agreement (No. 8920262), making Mendel a wholly-owned subsidiary of Novel Peptide.